1. Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma?
- Author
-
Vagios S, Doulgeraki T, Giannikaki E, Kavoura E, Papadimitriou C, Gakiopoulou H, and Pavlakis K
- Subjects
- Adult, Aged, Aged, 80 and over, Endometrial Neoplasms immunology, Endometrial Neoplasms pathology, Female, Humans, Middle Aged, Biomarkers, Tumor metabolism, DNA Mismatch Repair immunology, Endometrial Neoplasms therapy, Immunotherapy methods
- Abstract
Aim: To study whether mismatch repair (MMR) status is related to the expression of programmed cell death-ligand 1 (PD-L1) and CD8 counts in a series of grade 3 endometrial carcinomas., Materials and Methods: The expression of MMR protein PD-L1 and CD8
+ cell count were evaluated by immunohistochemistry and related to several clinicopathological parameters., Results: Among 105 endometrial carcinomas, 40% were of endometrioid and 60% of non-endometrioid histology. MMR deficiency was observed in 28.6% of cases and was related to endometrioid histology (p<0.001), positive PD-L1 expression (p=0.047) and high CD8+ cell count (p=0.022). When examined by histotype, endometrioid MMR-deficient tumors were related only to PD-L1 expression (p=0.032) but not to high CD8+ cell count (p=0.231), whereas non-endometrioid MMR-deficient carcinomas were not related to either of these markers. MMR deficiency was associated with PD-L1+ /CD8high status (p=0.006), whilst MMR proficiency was associated with PD-L1- /CD8low status. In MMR-proficient tumors, high CD8+ cell infiltration alone and combined with PD-L1- status was associated with better progression-free survival (p=0.013 and p=0.04, respectively)., Conclusion: MMR-deficient high-grade endometrioid tumors might be more likely to benefit from immunotherapy compared to other grade 3 endometrial carcinomas., (Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF